The GW-0742 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of GW-0742 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.
The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).
About GW-0742
GW-0742 is a synthetic research compound that acts as a selective agonist of the peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ). Activation of this nuclear receptor influences the expression of genes involved in lipid and glucose metabolism, energy regulation, inflammation, and other cellular processes.
Unlike selective androgen receptor modulators (SARMs), GW-0742 does not primarily act through the androgen receptor. It has been investigated mainly in preclinical studies examining metabolic, cardiovascular, and anti-inflammatory effects.
Key Features
- Targeted identification and quantification of GW-0742
- Suitable for pills, tablets, capsules, and raw API powders
- Analysis by HPLC
- Results for oral products reported in mg per tablet or capsule
- Results for raw API powders reported as percentage content
- Optional purity reporting in % (m/m) for raw API powders
- Minimum sample amount of three tablets or capsules
- Minimum sample amount of 200 mg for raw API powders
- Average turnaround time of 7 business days
Analysis Parameters
- Target compound: GW-0742
- CAS number: 317318-84-6
- Testing method: HPLC
- Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule
- Minimum content of target compound for evaluation in raw API powders: 10%
- Result format for oral products: mg per tablet or capsule
- Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]
- Minimum sample amount for oral products: Three tablets or capsules
- Minimum sample amount for raw API powders: 200 mg
- Average turnaround time: 7 business days
Important Notice
- This analysis is specifically intended for GW-0742. It does not automatically screen the sample for other PPAR agonists, SARMs, related compounds, contaminants, or undeclared substances.
- For oral products, the minimum amount of GW-0742 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.
- Purity reporting in % (m/m) is available only for raw API powders.
Optional Additional Analyses
The following optional laboratory services are available:
- Complete Raw Analytical Data
- Alternative Result Format: Purity in % (m/m) – only for raw API powders
- Batch Variance Testing
- Fentanyl Screening
- GC–MS Contamination Screening
- Heavy Metals Analysis (As, Cd, Pb, Hg)
- Additional Laboratory Report
